Single source drugs driving high prices

    KEY TAKEAWAY: Over the past seven years, generic drugs increased their share of total prescriptions filled from 66 percent to 82 percent, while brand drugs’ share of total prescriptions declined from 34 percent to 18 percent.

According to the Blue Cross report..

  • The rising cost of a narrow set of new drugs has resulted in the brand drug market maintaining 78 percent of total drug spending, roughly the same proportion it held in 2010.
  • Specifically, [inlinetweet prefix=”” tweeter=”” suffix=””]the cost of brand drugs with patent protection and no generic alternatives—commonly referred to as single-source drugs—is rising at an average annual rate of 25 percent [/inlinetweet](and 285 percent since 2010), more than double the 10 percent average annual rate of spending for all drugs.
  • [inlinetweet prefix=”” tweeter=”” suffix=””]These patent-protected single-source drugs now make up 63 percent of total drug spending, up from 29 percent of total spending in 2010[/inlinetweet], despite the fact that they comprise less than 10 percent of total prescriptions filled.
  • After a lower-cost generic drug is introduced, the resulting increase in the number of generic manufacturers and the generic share of the market for that drug consistently yields a reduction in total spending within a drug class.

Despite significant increases in the adoption rate for generics, brand drugs still comprise a dominant share of overall drug spending. As Exhibit 1 shows, generics have expanded from 66 percent of all prescriptions in 2010 to nearly 82 percent in 2016. The drop in the share of brand drugs, however, has not lessened their contribution to total prescription drug spending. In fact, that contribution has increased slightly from 77 percent to 78 percent. As generics approach 90 percent of all prescriptions, their rate of increase in share will inevitably begin to slow down. As a result, their ability to offset the rising cost of brand drugs through share growth will diminish.

Insight

This is old news as those of us who worked in the industry are aware.  Can pharma maintain this strategy?  Doubtful, but then again when has pharma ever been known as an innovative industry?